Bill Detail

H.R. 1627

Congress: 119

Title

TREATS Act

Summary

Telehealth Response for E-prescribing Addiction Therapy Services Act or the TREATS Act This bill permanently allows health care practitioners to prescribe certain controlled substances for treating substance use disorders via telehealth without evaluating the patient in person. Generally, a health care practitioner may not prescribe a controlled substance via telehealth unless they first conduct an in-person medical evaluation. Federal regulations currently provide a temporary exception to this requirement, allowing practitioners to prescribe schedule II-V controlled substances for legitimate medical purposes (such as treating substance use disorders) via telehealth without an in-person evaluation. However, this temporary regulatory flexibility expires on December 31, 2025. The bill permanently allows practitioners to prescribe schedule III-V controlled substances for the treatment of a substance use disorder via telehealth without conducting an in-person evaluation. In such instances, a practitioner may conduct a telehealth evaluation using audio-only or audio and video equipment.

Sponsor

Rep. Donald Norcross [D-NJ-1]

Status

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Status as of Jul 26, 2:34 PM · synced 18d ago

Introduced

2025-02-26

Data source mode: congress-gov

Bill Engagement

Lobbyists on the case

4 orgs · 27 lobbyists · 4 filings mention H.R. 1627 (TREATS Act) in LDA disclosures.
Top orgs filing
Lobbyists on this bill
+ 25 more in the full intelligence view

Prepared intelligence brief

Put this record in the joined picture.

Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.

Get your intelligence briefAlready a customer? Sign inGet free intelligence alerts →